58 / 160
610
and scoring system for evaluation of liver lesions in morbidity
obese patients. Hepatology 2012; 56: 1751-59.
22. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA,
Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading
and staging the histological lesions. AmGastroenterol1999;
94:2467-74.
23. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ,
Cummings OW, et al. Design andvalidation of a histological
schoring system for nonalcoholic fatty liver disease. Hepatology
2005; 41:1313–21.
24. Sumida, Nakajima A, Itoh Y. Limitations of liver biopsy and
non-invasive diagnostic tests for the diagnosis of nonalcoholic
fatty liver disease/nonalcoholic steatohepatitis. W J Gastroenterol
2014; 14; 20(2): 475-85.
25. Nascimbeni F, Pais R, Bellentani S, et alFrom NAFLD in clinical
practice to answers from guidelines. J Hepatol. 2013;59:859-71.
26. Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC. Serum
activity of alanine aminotransferase (ALT) as an indicator of health
and disease. Hepatology 2008; 47: 1363-70.
27. Adams LA, Angulo P. Role of liver biopsy and serum markers of liver
fibrosis in non-alcoholic fatty liver disease. Clin Liver Dis 2007;
11(1): 25–35, viii.
28. Dixon JB, Bhathal PS, O`Brien PE: nonalcoholic fatty liver disease:
predictors of nonalcoholic steatohepatitis and liver fibrosis in the
severly obese. Gastroenterology 2001; 121: 91-100.
29. AidayAbeHTonita ,NaganoT,SekiN,SugitaT,etal.Serumcytokeratin
18 fragment level as a noninvasive biomarker for nonalcoholic fatty
liver disease. Int J Clin Exp Med 2014;7:4191-98.
30. Tanwar S, Trembling PM, Guha IN, et al. Validation of terminal
peptide of procollagen III for the detection and assessment of
nonalcoholic steatohepatitis in patient with nonalcoholic fatty
liver disease. Hepatol 2013; 57:103-111.
31. Mishra P, Younossi ZM. Abdominal ultrasound for diagnosis of
nonalcoholic fatty liver disease (NAFLD). Am Gastroenterol 2007;
102: 2716–7.
32. Charatcharoenwitthaya P, Lindor KD. Role of radiologic modalities
in the management of non-alcoholic steatohepatitis. Clin Liver
Dis 2007; 11: 37–54.
33. Machado MV, Cortez-Pinto H. Non-alcoholic fatty liver disease:
what the clinician needs to know. W J Gastroenterol 2014;
20(36):12956-80.
34. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A
position statement on NAFLD/NASH based on the EASL 2009
special conference. J Hepatol 2010; 53:372–84.
35. Expert Panel on Detection, Evaluation, and Treatment of High
Blood Cholesterol in Adults.Executive Summary ofThe Third Report
ofThe National Cholesterol Education Program(NCEP) Expert
Panel on Detection, Evaluation, And Treatment of High Blood
Cholesterol In Adults (Adult Treatment Panel III).JAMA 2001 16;
285(19):2486-97.
36. Ryan MC, Wilson AM, Slavin J et al. Associations between liver
histology and severity of the metabolic syndrome in subjects with
nonalcoholic fatty liver disease. Diabetes Care 2005; 28:1222–4.
37. Yoshioka K, Hashimoto S, Kawabe N. Measurement of liver stiffness
biopsy: a prospective study. Gastroenterology2011; 140(1):124-
31.
6. Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R. Prevalence of
primary non-alcoholic fatty liver disease in a population-based
study and its association with biochemical and anthropometric
measures. Liver Int. 2006; 26:856-63.
7. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani
S. Prevalence of and risk factors for nonalcoholic fatty liver disease:
the Dionysos nutrition and liver Study. Hepatology. 2005; 42:44-
52.
8. Vernon G, Baranova A, Younossi ZM. Systematic review: the
epidemiology and natural history of non-alcoholic fatty liver
disease and non-alcoholic steatohepatitis in adults. Aliment
Pharmacol ther 2011; 34:274–85.
9. Hashimoto E, Taniai M, and Tokushige K. Characteristics and
diagnosis of NAFLD/NASH. J Gastroenterology Hepatol 2013; 28
(4): 64–70.
10. Eguchi Y, Hyogo H, Ono M et al. Prevalence and associated
metabolic factors of nonalcoholic fatty liver disease in the general
population from 2009 to 2010 in Japan: a multicenter large
retrospective study. J Gastroenteroly 2012; 47: 586–95.
11. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC,
McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of
clinical and pathological severity. Gastroenterology 1999;116:
1413-19.
12. Hui JM, Kench JG, Chitturi S, et al. Long-term outcomes of cirrhosis
in nonalcoholic steatohepatitis compared with hepatitis C.
Hepatology 2003;38:420-42.
13. Adams LA, Lymp JF, St Sauver J. The natural history of
nonalcoholic fatty liver disease: a population-based cohort study.
Gastroenterology 2005; 129(1):113-21.
14. Ratziu VD, Bonyhay L, Di Martino V, et al. Survival, liver failure, and
hepatocellularcarcinoma in obesity-related cryptogenic cirrhosis.
Hepatology 2002; 35:1485-93.
15. Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular
carcinoma: two growing epidemics with a potential link. Cancer
2009:115:5651-61.
16. Starley BQ, Calcagno CJ, Harrison SA Nonalcoholic fatty liver
disease and hepatocellular carcinoma: a weighty connection.
Hepatology 2010 ; 51(5):1820-32.
17. Encuesta nacional de salud ENS Chile 2009-2010. Pontificia
Universidad Católica de Chile.
18. Riquelme A, Arrese M, Soza A. Non-alcoholic fatty liver disease
and its association with obesity, insulin resistance and increased
serum levels of C-reactive protein in Hispanics. Liver Int2009; 29:
82-8.
19. NguyenTAT, Sanyal AJ. Pathophysiology guided treatment of
nonalcoholic steatohepatitis. J Gastroenterol Hepatol 2012; 27:
58-64.
20. Gruen ML, Hao M, Piston DW, Hasty AH.Leptin requires canonical
migratory signaling pathways for induction of monocyte and
macrophage chemotaxis. Am J Physiol Cell Physiol 2007; 293:
1481-1488.
21. Bedossa P, Poitou C, Veyrie N, et al: Histopathological algorithm
[REV. MED. CLIN. CONDES - 2015; 26(5) 600-612]